Showing 1 - 4 results of 4 for search 'Benoît Sansas', query time: 0.03s Refine Results
  1. 1
    A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

    A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model by Roland Kratzer, Benoît Sansas, Karine Lélu, Alexei Evlachev, Doris Schmitt, Nathalie Silvestre, Geneviève Inchauspé, Perrine Martin

    Published 2018-06-01
    Get full text
    Article
  2. 2
    Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

    Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and M... by Christelle Remy-Ziller, Christine Thioudellet, Julie Hortelano, Murielle Gantzer, Virginie Nourtier, Marie-Christine Claudepierre, Benoit Sansas, Xavier Préville, Kaïdre Bendjama, Eric Quemeneur, Karola Rittner

    Published 2018-01-01
    Get full text
    Article
  3. 3
    Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

    Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial by Fabien Zoulim, Claire Fournier, François Habersetzer, Martin Sprinzl, Stanislas Pol, Carla S Coffin, Vincent Leroy, Mang Ma, Heiner Wedemeyer, Ansgar W Lohse, Robert Thimme, Karine Lugardon, Perrine Martin, Bérangère Bastien, Benoit Sansas, Nathalie Adda, Celine Halluard, Kaïdre Bendjama, Maud Brandely, Geneviève Inchauspé

    Published 2020-02-01
    Get full text
    Article
  4. 4
    A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

    A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. by Stéphane Leung-Theung-Long, Charles-Antoine Coupet, Marie Gouanvic, Doris Schmitt, Aurélie Ray, Chantal Hoffmann, Huguette Schultz, Sandeep Tyagi, Heena Soni, Paul J Converse, Lilibeth Arias, Patricia Kleinpeter, Benoît Sansas, Khisimuzi Mdluli, Cristina Vilaplana, Pere-Joan Cardona, Eric Nuermberger, Jean-Baptiste Marchand, Nathalie Silvestre, Geneviève Inchauspé

    Published 2018-01-01
    Get full text
    Article

Search Tools: